| Title |
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
|
|---|---|
| Published in |
Current Oncology Reports, January 2013
|
| DOI | 10.1007/s11912-012-0290-4 |
| Pubmed ID | |
| Authors |
Thierry Conroy, Céline Gavoille, Emmanuelle Samalin, Marc Ychou, Michel Ducreux |
| Abstract |
In 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Netherlands | 1 | 1% |
| Unknown | 87 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 13% |
| Student > Ph. D. Student | 11 | 12% |
| Researcher | 10 | 11% |
| Student > Master | 10 | 11% |
| Student > Bachelor | 8 | 9% |
| Other | 15 | 17% |
| Unknown | 23 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 47% |
| Biochemistry, Genetics and Molecular Biology | 6 | 7% |
| Agricultural and Biological Sciences | 5 | 6% |
| Engineering | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 7 | 8% |
| Unknown | 24 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2021.
All research outputs
#7,455,523
of 22,792,160 outputs
Outputs from Current Oncology Reports
#300
of 880 outputs
Outputs of similar age
#85,007
of 280,832 outputs
Outputs of similar age from Current Oncology Reports
#4
of 5 outputs
Altmetric has tracked 22,792,160 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 880 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,832 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one.